DDR kinase inhibitors, such as those targeting PARP, ATM, ATR, DNA-PK, CHK1/2, BER, and WEE1, have been tested in clinical trials as a way to kill tumor cells, as cancer cells are more sensitive to compromised repair systems compared to normal cells (Table 1) [89,221]. Here, ATR is linked to cancer.